Products for Research Use Only

BRD4-BD1/2-IN-3

CAT: 0804-HY-178041-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-178041-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BRD4-BD1/2-IN-3 (Compound B6) is a selective BRD4 BD2 inhibitor with an IC50 of 0.41 nM for BRD4 BD2 over BRD4 BD1. BRD4-BD1/2-IN-3 significantly inhibits the LPS -induced expression of IL-6. BRD4-BD1/2-IN-3 shows anti-inflammatory activities by modulating the TNF and NF-κB signaling pathway. BRD4-BD1/2-IN-3 can be used for inflammatory diseases research[1].
UNSPSC
12352005
Target
C-Fms; Epigenetic Reader Domain; Interleukin Related; NF-κB; TNF Receptor
Related Pathways
Apoptosis; Epigenetics; Immunology/Inflammation; NF-κB; Protein Tyrosine Kinase/RTK
Field of Research
Inflammation/Immunology
Purity
99.52
Solubility
DMSO : 8.33 mg/mL (ultrasonic)
Smiles
O=C1NC(C2=CN(N=C2)CC3=CC=CC=C3)=NC4=CC(OC)=CC(OC)=C41
Molecular Formula
C20H18N4O3
Molecular Weight
362.38
References & Citations
[1]Chen S, et al. Discovery of 2- (Pyrazol-4-yl) -quinazolin-4 (3H) -one Derivatives as Subnanomolar BRD4 BD2 Inhibitors with High Selectivity via a Bioisosterism Approach. J Med Chem. 2025 Sep 11;68 (17) :18314-18334.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BD1; BD2; IL-1; IL-6; RelA/p65